日前，海问香港办公室助力中国宝原投资有限公司（“中国宝原”）就中国核工业集团有限公司（“中核集团”）将其直接持有的全部106,676,903股中国同辐股份有限公司（“中国同辐”，1763.HK）的内资股（约占中国同辐全部已发行股本总额的33.35%）无偿划转（“无偿划转”）至中国宝原顺利完成。本次无偿划转完成后，中国宝原成为中国同辐的直接控股股东，而中核集团仍为中国同辐的最终控制股东。

中核集团于1999年6月29日成立，是经国务院批准组建、中央直接管理的国有重要骨干企业，是国家核科技工业的主体、核能发展与核电建设的中坚、核技术应用的骨干，拥有完整的核科技工业体系。中国宝原为中核集团全资子公司，致力于落实中核集团核技术应用产业发展中长期战略，业务覆盖核技术应用绝大部分领域，形成了从技术、产品到服务应用的产业链。通过整合研发、生产、销售和服务，中国宝原巩固了其在核技术行业与医学应用领域的领先地位。中国同辐为香港联交所主板上市公司，自1983年成立以来，在核技术应用领域已深耕40年，聚焦药品的研发、生产、销售，同时兼营放射源、辐照、核医疗装备和独立医学检验实验室服务，是国内核技术应用领域的领军企业。

海问香港办公室作为中国宝原的香港法律顾问，全面配合客户需要，就本次无偿划转所涉法律法规及其他重大问题适时与各方进行沟通和交流。海问香港办公室凭借其对香港法律法规以及各监管机构的规则与指引等的扎实理解和丰富的交易类法律服务经验，就项目方案整体规划、审阅交易文件、遵守信息披露义务、相关豁免申请、与监管部门沟通等方面，为客户提供了专业的法律建议和及时且适切的全流程解决方案，助力本次无偿划转顺利完成。海问香港办公室在本项目中提供的高质及高效的法律服务获得了客户的高度评价。

Recently, Haiwen Hong Kong assisted China Baoyuan Investment Co., Ltd. (“China Baoyuan”) in successful completion of the gratuitous transfer by China National Nuclear Corporation (“CNNC”) of all 106,676,903 domestic shares in China Isotope & Radiation Corporation (“CIRC”, 1763.HK) directly held by it (the “Gratuitous Transfer”), representing approximately 33.35% of CIRC’s total issued share capital, to China Baoyuan. Upon completion of the Gratuitous Transfer, China Baoyuan has become a direct controlling shareholder of CIRC, while CNNC remains the ultimate controlling shareholder of CIRC.

CNNC was established on 29 June 1999 as approved by the State Council and is a state-owned backbone enterprise directly administered by the central government. Equipping with a complete nuclear science and technology industry system, CNNC plays a key role in the fields of national nuclear science and technology industry, nuclear energy development and nuclear power construction, and nuclear technology application. China Baoyuan is a wholly-owned subsidiary of CNNC and specialises in implementing CNNC’s medium and long-term development strategy for its nuclear technology application business, forging an industry chain that covers most aspects of nuclear technology application, from technology, products to service applications. China Baoyuan cemented its lead in the nuclear technology industry and in medical applications through its integration of research and development, production, sales, and services. CIRC, a company listed on the main board of The Stock Exchange of Hong Kong, has been exploring the field of nuclear technology application for 40 years since its establishment in 1983. As a leading enterprise in the nuclear technology application industry in China, CIRC focuses on research and development, manufacturing, sales of pharmaceuticals and is also engaged in radioactive sources, irradiation, nuclear medical equipment and independent clinical laboratory services.

As the Hong Kong legal adviser to China Baoyuan, Haiwen Hong Kong has fully accommodated the needs of its client, as well as timely communicated and exchanged views with various professional parties on the relevant laws and regulations and other material issues involved in the Gratuitous Transfer. With its solid understanding of Hong Kong laws and regulations and the rules and guidelines of various regulatory bodies, as well as extensive experience in transactional legal services, Haiwen Hong Kong provided professional legal advice and timely and appropriate solutions to its client at all stages of the project on overall transactional structure design, reviewing of transaction documents, fulfilling public information disclosure obligations, waiver applications, and communication with regulatory authorities, etc. which are instrumental to the successful completion of the Gratuitous Transfer. Haiwen Hong Kong has received high acclaim from its client for the high-quality and efficient legal services provided in this project.

The team from Haiwen advising on this project was led by international partner Isaac Chen, and assisted by associates Henry Ho, Anna Mak, Yuda Chen and Aiye Jia, and paralegal Xuanchi Jing.